AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece
Completed
- Conditions
- Heart Failure
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 257
- Registration Number
- NCT05635331
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD5055 solution for infusionDrug: AZD5055 film-coated tabletDrug: AZD5055 oral suspensionDrug: Rabeprazole, Delayed-release tablet
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT05630677
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1174
- Registration Number
- NCT05629585
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT05629234
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Phase 3
Recruiting
- Conditions
- Viral Lung Infection and Acute Respiratory Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2870
- Registration Number
- NCT05624450
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 291
- Registration Number
- NCT05603845
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Terminated
- Conditions
- Breast Cancer
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 78
- Registration Number
- NCT05592483
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT05587998
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Phase 3
Recruiting
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Other: Placebo
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT05583227
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: BGF MDI HFO 320/14.4/9.6 μgDrug: BGF MDI HFA 320/14.4/9.6 μg
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 559
- Registration Number
- NCT05573464
- Locations
- 🇬🇧
Research Site, Thetford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath